secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-04-25T23:59:59+00:00
Accession:  0001615219-25-000045
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharma receives Nasdaq delisting notice for bid price non-compliance; merger with Decoy planned
--------------------------------------------------------------------------------

- Nasdaq notice on April 23, 2025 for failing minimum $1.00 bid price for 30 consecutive business days.
- Ineligible for compliance period due to prior reverse stock split; also non-compliant with $2.5M equity standard.
- Unless appeal by April 30, 2025, suspension and delisting scheduled for May 2, 2025; company intends to appeal.
- Plans to present merger with Decoy Therapeutics Inc. to regain compliance at Nasdaq Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000045/0001615219-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000045/flks-20250423.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer